| 发明名称 |
AN INHALABLE MEDICAMENT |
| 摘要 |
Accordingly, the present invention provides a solution formulation for inhalation comprising: a liquid phase; an active ingredient having a functional group which is susceptible to hydrolysis and/or solvolysis, dissolved in the liquid phase; and a magnesium or calcium salt, dissolved in the liquid phase. The formulation is particularly suited to pMDIs and nebulisers. |
| 申请公布号 |
US2016250197(A1) |
申请公布日期 |
2016.09.01 |
| 申请号 |
US201414419803 |
申请日期 |
2014.11.21 |
| 申请人 |
Teva Branded Pharmaceutical Products R&D, Inc. |
发明人 |
Dalvi Mukul;Wu Libo |
| 分类号 |
A61K31/439;A61M11/00;A61K47/02;A61M15/00;A61K9/00;A61K47/10 |
主分类号 |
A61K31/439 |
| 代理机构 |
|
代理人 |
|
| 主权项 |
1. A solution formulation for inhalation comprising:
a liquid phase;
an active ingredient having a functional group which is susceptible to hydrolysis and/or solvolysis, dissolved in the liquid phase; and at least one of a magnesium or calcium salt, dissolved in the liquid phase. |
| 地址 |
Horsham PA US |
